Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-23-034496
Filing Date
2023-07-25
Accepted
2023-07-25 17:19:54
Documents
15
Period of Report
2023-09-06

Document Format Files

Seq Description Document Type Size
1 PRE 14A tcon-20230724.htm   iXBRL PRE 14A 296548
2 GRAPHIC img19860071_0.jpg GRAPHIC 12234
3 GRAPHIC img19860071_1.jpg GRAPHIC 556002
4 GRAPHIC img19860071_2.jpg GRAPHIC 983636
  Complete submission text file 0000950170-23-034496.txt   4136769

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tcon-20230724_pre.xml EX-101.PRE 2774
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tcon-20230724_lab.xml EX-101.LAB 3164
7 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tcon-20230724.xsd EX-101.SCH 2476
9 EXTRACTED XBRL INSTANCE DOCUMENT tcon-20230724_htm.xml XML 1305
Mailing Address 4350 LA JOLLA VILLAGE DRIVE SUITE 800 San Diego CA 92122
Business Address 4350 LA JOLLA VILLAGE DRIVE SUITE 800 San Diego CA 92122 858-550-0780
Tracon Pharmaceuticals, Inc. (Filer) CIK: 0001394319 (see all company filings)

EIN.: 342037594 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-36818 | Film No.: 231109477
SIC: 2836 Biological Products, (No Diagnostic Substances)